☆ 4.7 Review

Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021

BIOMEDICINES (2022)

Related references

Note: Only part of the references are listed.

Article Pharmacology & Pharmacy

Efgartigimod: First Approval

Young-A Heo

Summary: Efgartigimod is a novel drug developed by argenx for the treatment of autoimmune diseases, including myasthenia gravis. It received its first approval in the USA in 2021 and is currently being evaluated and registered in other countries. Numerous clinical studies are also investigating the use of Efgartigimod in various other autoimmune diseases.

DRUGS (2022)

Add to Collection

Review Biochemistry & Molecular Biology

The Pharmaceutical Industry in 2021. An Analysis of FDA Drug Approvals from the Perspective of Molecules

Beatriz G. de la Torre et al.

Summary: Similar to last year, 2021 will be remembered for the COVID-19 pandemic. Despite the approval of five vaccines, the pandemic remains uncontrolled. However, there have been significant drug approvals by the FDA, with 50 drugs authorized in 2021. Nitrogen aromatic heterocycles and fluorine atoms continue to be predominant among small molecules.

MOLECULES (2022)

Add to Collection

Article Clinical Neurology

Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease

Melanie D. Whittington et al.

Summary: Aducanumab treatment resulted in minimal health improvements at a considerable cost, leading to incremental cost-effectiveness ratios that far exceeded commonly used value thresholds, even under optimistic treatment effectiveness assumptions. The annual price needed to meet commonly used cost-effectiveness thresholds ranged from $2,950 to $8,360, representing a significant discount from the manufacturer's annual launch price of $56,000.

NEUROLOGY (2022)

Add to Collection

Article Pediatrics

Lonapegsomatropin: Pediatric First Approval

Yvette N. Lamb

Summary: Lonapegsomatropin is a long-acting prodrug of somatropin developed by Ascendis Pharma for the treatment of growth hormone deficiency in pediatric and adult patients. It received its first approval in the USA in August 2021 for pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone, allowing for once-weekly subcutaneous injections.

PEDIATRIC DRUGS (2022)

Add to Collection

Article Neurosciences

Making the Case for Accelerated Withdrawal of Aducanumab

Peter Whitehouse et al.

Summary: The FDA's controversial approval of aducanumab for Alzheimer's disease in June 2021 has raised significant concerns due to its lack of clinical efficacy evidence, safety issues, and high cost. In December 2021, an international group recommended the withdrawal of FDA approval for aducanumab, supporting the filing of a formal Citizen Petition by the Right Care Alliance.

JOURNAL OF ALZHEIMERS DISEASE (2022)

Add to Collection

Article Medicine, General & Internal

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

Geert D'Haens et al.

LANCET (2022)

Add to Collection

Article Medicine, Research & Experimental

International nonproprietary names for monoclonal antibodies: an evolving nomenclature system

Sofia S. Guimaraes Koch et al.

Summary: Appropriate nomenclature is crucial for pharmaceutical substances and their development. The WHO INN Programme has revised the naming system for antibody-based drugs and introduced new stems to address the challenge of distinguishing names.

MABS (2022)

Add to Collection

Review Geriatrics & Gerontology

Role of Aducanumab in the Treatment of Alzheimer?s Disease: Challenges and Opportunities

Miguel Vaz et al.

Summary: This review summarizes the clinical development of aducanumab until regulatory agencies' decisions, the available trials data, and the controversy over aducanumab approval for Alzheimer's disease (AD).

CLINICAL INTERVENTIONS IN AGING (2022)

Add to Collection

Article Oncology

FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma

Elaine Chang et al.

Summary: Enfortumab vedotin-ejfv has been granted accelerated approval by the FDA for the treatment of locally advanced or metastatic urothelial cancer. The drug showed certain efficacy in clinical trials but also comes with a high rate of adverse reactions. This approval is subject to further verification and description of clinical benefits in confirmatory trials.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Review Allergy

Cost-Effectiveness of Biologics for Allergic Diseases

Ann Chen Wu et al.

Summary: The introduction of specific humanized monoclonal antibodies has significantly changed the treatment of allergic diseases in the past 20 years, with 5 mAbs now licensed for various indications. Understanding the cost-effectiveness of biologics is crucial given their high costs. Conducting cost-effectiveness evaluations alongside efficacy trials will assist decision-making for patients, providers, payers, and policymakers as biologics continue to play a larger role in treating allergic diseases.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Add to Collection

Article Pharmacology & Pharmacy

Avalglucosidase alfa: First Approval

Sohita Dhillon

Summary: Avalglucosidase alfa is a novel drug developed for the treatment of Pompe disease, which has received approvals in the USA and EU, with regulatory reviews ongoing in the UK and Japan while clinical studies are being conducted worldwide.

DRUGS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Tisotumab Vedotin: First Approval

Anthony Markham

Summary: Tisotumab vedotin, an antibody-drug conjugate targeting tissue factor expressing tumors, has received accelerated approval in the US for the treatment of cervical cancer. This approval marks a significant milestone in its development.

DRUGS (2021)

Add to Collection

Review Biochemistry & Molecular Biology

The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules

Beatriz G. de la Torre et al.

Summary: In 2020, a total of 53 new drugs were approved by the US FDA, including 40 new chemical entities and 13 biologics. The approved drugs consist of monoclonal antibodies, antibody-drug conjugates, peptides, and oligonucleotides, with a notable presence of fluorine atoms and/or nitrogen aromatic heterocycles. These new drugs are classified based on their chemical structures as biologics, TIDES, natural products, fluorine-containing molecules, nitrogen aromatic heterocycles, and other small molecules.

MOLECULES (2021)

Add to Collection

Review Hematology

Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma

Larysa Sanchez et al.

Summary: Daratumumab is a human immunoglobulin G1 kappa monoclonal antibody that targets CD38 and has been approved for use in both newly diagnosed and relapsed refractory multiple myeloma. The subcutaneous formulation of daratumumab has shorter administration time, lower rates of infusion-related reactions, and smaller infusion volume compared to the intravenous formulation. Despite these differences, the pharmacokinetics, safety profile, and efficacy are comparable between the two formulations.

THERAPEUTIC ADVANCES IN HEMATOLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Secukinumab: A Review in Psoriatic Arthritis

Hannah A. Blair

Summary: Secukinumab is an effective treatment for PsA across all key domains, with low rates of adverse effects and sustained long-term efficacy. It is a useful alternative to TNFi and other bDMARDs for adult patients with active PsA.

DRUGS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Naxitamab: First Approval

Anthony Markham

Summary: Naxitamab is a humanised anti-GD2 monoclonal antibody developed for the treatment of neuroblastoma and other GD2-positive cancers, which has recently received accelerated approval from the US FDA. This antibody, in combination with a cell-stimulating factor, demonstrates therapeutic effects in patients with partial response, minor response, or stable disease.

DRUGS (2021)

Add to Collection

Article Medicine, General & Internal

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

Thomas Powles et al.

Summary: Enfortumab vedotin significantly prolonged survival compared with standard chemotherapy in patients with advanced urothelial carcinoma who had previously received platinum-based treatment and a PD-1 or PD-L1 inhibitor, as well as showing better progression-free survival outcomes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Donanemab in Early Alzheimer's Disease

Mark A. Mintun et al.

Summary: In this study, donanemab showed improved composite scores for cognition and daily living activities compared to placebo in patients with early Alzheimer's disease at 76 weeks, although secondary outcomes varied. Longer and larger trials are needed to further explore the efficacy and safety of donanemab in Alzheimer's disease.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

News Item Medicine, General & Internal

Aducanumab: 4 in 10 high dose trial participants experienced brain swelling or bleeding

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Review Pharmacology & Pharmacy

Evinacumab: First Approval

Anthony Markham

Summary: Evinacumab, a recombinant human monoclonal antibody, has been approved for the treatment of HoFH and severe hypertriglyceridemia in the USA, and has received a positive opinion in the EU. This milestone in evinacumab's development highlights its efficacy in managing various lipid disorders.

DRUGS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Ansuvimab: First Approval

Arnold Lee

Summary: Ansuvimab, developed by Ridgeback Biotherapeutics, is a human monoclonal antibody approved in the USA for treating Zaire ebolavirus infection in both adult and paediatric patients. It blocks the entry of Ebola virus into host cells by binding to the virus glycoprotein.

DRUGS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Margetuximab: First Approval

Anthony Markham

Summary: Margetuximab, a second-generation anti-HER2 monoclonal antibody, has been approved in the USA for the treatment of previously-treated metastatic HER2-positive breast cancer, based on its improved binding to activating Fc gamma receptor IIIA and reduced binding to inhibitory Fc gamma receptor IIB, aiming to enhance response rates.

DRUGS (2021)

Add to Collection

Review Immunology

Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond

Charalampos Theocharopoulos et al.

Summary: ADCs combine the high selectivity and specificity of monoclonal antibodies with the cytotoxic potency of attached payloads. Ten ADCs have been approved by FDA for oncological indications, with many others currently being tested in clinical and preclinical level. Explore bioengineering breakthroughs such as bispecific mAbs, dual-drug platforms, novel linkers, and conjugation chemistries to enhance the effectiveness and safety of immunoconjugates.

VACCINES (2021)

Add to Collection

Article Medicine, General & Internal

Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma

Andrew Menzies-Gow et al.

Summary: Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin, effectively reduces asthma exacerbations in patients with severe, uncontrolled asthma, leading to improved lung function, asthma control, and quality of life.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Pharmacology & Pharmacy

Dostarlimab: First Approval

Anthony Markham

Summary: Dostarlimab, a humanized monoclonal antibody PD-1 receptor antagonist, has been approved for the treatment of various cancers in the EU and USA. This marks a significant milestone in the development of the drug.

DRUGS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Anifrolumab: First Approval

Emma D. Deeks

Summary: Anifrolumab is a monoclonal antibody antagonist of the type 1 interferon receptor, developed for the treatment of autoimmune disorders including SLE and lupus nephritis. It has been approved for use in the USA for adult patients with moderate to severe SLE, with ongoing clinical studies in other countries. This marks a significant milestone in the development of anifrolumab for the treatment of SLE.

DRUGS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Loncastuximab Tesirine: First Approval

Arnold Lee

Summary: Loncastuximab tesirine is an antibody-drug conjugate developed for the treatment of B cell lymphomas, currently approved in the US for specific types of lymphoma treatment while being researched for treatments of other types of lymphoma.

DRUGS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Amivantamab: First Approval

Yahiya Y. Syed

Summary: Amivantamab, a bispecific monoclonal antibody targeting EGFR and MET for NSCLC, has received approval in the USA and is undergoing preregistration in multiple countries worldwide.

DRUGS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Aducanumab: First Approval

Sohita Dhillon

Summary: Aducanumab is a monoclonal antibody developed for the treatment of Alzheimer's disease, targeting aggregated forms of amyloid beta. It has received approval in the USA for use in patients with mild cognitive impairment or mild dementia. Ongoing studies are evaluating its safety and efficacy in patients with early Alzheimer's disease.

DRUGS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Tralokinumab: First Approval

Sean Duggan

Summary: Tralokinumab, a human IgG4 monoclonal antibody developed by LEO Pharma, has been approved in the EU for the treatment of moderate-to-severe atopic dermatitis. This approval was based on its ability to specifically bind to IL-13 and inhibit its interaction with the IL-13 receptor, neutralizing the cytokine's biological activity.

DRUGS (2021)

Add to Collection

Editorial Material Clinical Neurology

The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA

Jason Karlawish et al.

Summary: The FDA's accelerated approval of aducanumab for Alzheimer's disease treatment has a broad label, overlooking key aspects of the scientific process, which may erode public trust in research and regulatory science.

NATURE REVIEWS NEUROLOGY (2021)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn's Disease: Results from the phase 3 ADVANCE and MOTIVATE studies

S. W. Schreiber et al.

JOURNAL OF CROHNS & COLITIS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Atoltivimab/maftivimab/odesivimab (Inmazeb) combination to treat infection caused by Zaire ebolavirus

D. Saxena et al.

Summary: Zaire ebolavirus has caused catastrophic outbreaks with high mortality rates and Inmazeb is the first FDA-approved treatment for this infection, displaying significant efficacy in clinical trials.

DRUGS OF TODAY (2021)

Add to Collection

Article Oncology

FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer

Jennifer J. Gao et al.

Summary: On June 29, 2020, the FDA approved Phesgo for the treatment of patients with HER2-positive breast cancer based on the FeDeriCa trial, which demonstrated the comparability of subcutaneous and intravenous usage. This approval allows for extrapolation to all breast cancer indications approved for intravenous trastuzumab and pertuzumab.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Immunology

Comparison of elapegademase and pegademase in ADA-deficient patients and mice

L. Murguia-Favela et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)

Add to Collection

Article Pharmacology & Pharmacy

Crizanlizumab: First Approval

Hannah A. Blair

DRUGS (2020)

Add to Collection

Article Pharmacology & Pharmacy

Luspatercept: First Approval

Anthony Markham

DRUGS (2020)

Add to Collection

Article Endocrinology & Metabolism

Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial

Gudmundur Johannsson et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)

Add to Collection

Article Endocrinology & Metabolism

Vestronidase alfa: Recombinant human β-glucuronidase as an enzyme replacement therapy for MPS VII

Jaclyn Cadaoas et al.

MOLECULAR GENETICS AND METABOLISM (2020)

Add to Collection

Review Biochemistry & Molecular Biology

The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules

Beatriz G. de la Torre et al.

MOLECULES (2020)

Add to Collection

Review Pharmacology & Pharmacy

Cenegermin: A Review in Neurotrophic Keratitis

Emma D. Deeks et al.

DRUGS (2020)

Add to Collection

Article Pharmacology & Pharmacy

Eptinezumab: First Approval

Sohita Dhillon

DRUGS (2020)

Add to Collection

Article Pharmacology & Pharmacy

Trastuzumab Deruxtecan: First Approval

Susan J. Keam

DRUGS (2020)

Add to Collection

Article Pharmacology & Pharmacy

Teprotumumab: First Approval

Anthony Markham

DRUGS (2020)

Add to Collection

Article Pharmacology & Pharmacy

Isatuximab: First Approval

Sohita Dhillon

DRUGS (2020)

Add to Collection

Review Immunology

Immunogenicity of Protein Therapeutics: A Lymph Node Perspective

Kristy Fu et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Pharmacology & Pharmacy

Inebilizumab: First Approval

James E. Frampton

DRUGS (2020)

Add to Collection

Article Pharmacology & Pharmacy

Sacituzumab Govitecan: First Approval

Yahiya Y. Syed

DRUGS (2020)

Add to Collection

Review Pharmacology & Pharmacy

Tafasitamab: First Approval

Sheridan M. Hoy

DRUGS (2020)

Add to Collection

Article Pharmacology & Pharmacy

Satralizumab: First Approval

Young-A Heo

DRUGS (2020)

Add to Collection

Article Pharmacology & Pharmacy

Belantamab Mafodotin: First Approval

Anthony Markham

DRUGS (2020)

Add to Collection

Review Biotechnology & Applied Microbiology

Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data

Guillaume Beziat et al.

ONCOTARGETS AND THERAPY (2020)

Add to Collection

Editorial Material Hematology

Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm

Naveen Pemmaraju et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Primary Health Care

Trends in FDA drug approvals over last 2 decades: An observational study

Angelika Batta et al.

JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE (2020)

Add to Collection

Article Pharmacology & Pharmacy

Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera

S. M. Wagner et al.

DRUGS OF TODAY (2020)

Add to Collection

Review Immunology

Bezlotoxumab

Stuart Johnson et al.

CLINICAL INFECTIOUS DISEASES (2019)

Add to Collection

Editorial Material Biotechnology & Applied Microbiology

The Increasingly Human and Profitable Monoclonal Antibody Market

Antonio L. Grilo et al.

TRENDS IN BIOTECHNOLOGY (2019)

Add to Collection

Review Medicine, General & Internal

Pegvaliase: a novel treatment option for adults with phenylketonuria

Karlie C. Mahan et al.

CURRENT MEDICAL RESEARCH AND OPINION (2019)

Add to Collection

Article Pharmacology & Pharmacy

Ravulizumab: First Global Approval

Kate McKeage

DRUGS (2019)

Add to Collection

Article Pharmacology & Pharmacy

Romosozumab: First Global Approval

Anthony Markham

DRUGS (2019)

Add to Collection

Article Pharmacology & Pharmacy

Tagraxofusp: First Global Approval

Yahiya Y. Syed

DRUGS (2019)

Add to Collection

Review Oncology

Antibody-Drug Conjugate-Based Therapeutics: State of the Science

Michael J. Birrer et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)

Add to Collection

Review Biochemistry & Molecular Biology

The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules

Beatriz G. de la Torre et al.

MOLECULES (2019)

Add to Collection

Review Clinical Neurology

Therapeutic landscape for Batten disease: current treatments and future prospects

Tyler B. Johnson et al.

NATURE REVIEWS NEUROLOGY (2019)

Add to Collection

Article Pharmacology & Pharmacy

Risankizumab: First Global Approval

Kate McKeage et al.

DRUGS (2019)

Add to Collection

Article Pharmacology & Pharmacy

Polatuzumab Vedotin: First Global Approval

Emma D. Deeks

DRUGS (2019)

Add to Collection

Article Pharmacology & Pharmacy

Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma

Giancarlo Marone et al.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)

Add to Collection

Review Medicine, General & Internal

Antibody-drug conjugates for cancer

Cindy H. Chau et al.

LANCET (2019)

Add to Collection

Article Pharmacology & Pharmacy

Brolucizumab: First Approval

Anthony Markham

DRUGS (2019)

Add to Collection

Article Medicine, General & Internal

Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

Takashi Yamamura et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Review Oncology

Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer

Young-A Heo et al.

TARGETED ONCOLOGY (2019)

Add to Collection

Review Biochemistry & Molecular Biology

Natural Products and Synthetic Analogs as a Source of Antitumor Drugs

Javad Sharifi-Rad et al.

BIOMOLECULES (2019)

Add to Collection

Article Pharmacology & Pharmacy

Emapalumab: First Global Approval

Zaina T. Al-Salama

DRUGS (2019)

Add to Collection

Article Dermatology

Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice

Jorge R. Georgakopoulos et al.

JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2019)

Add to Collection

Review Biochemistry & Molecular Biology

Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis

Stanley L. Cohan et al.

BIOMEDICINES (2019)

Add to Collection

Article Pharmacology & Pharmacy

Emicizumab-kxwh: First Global Approval

Lesley J. Scott et al.

DRUGS (2018)

Add to Collection

Article Pharmacology & Pharmacy

Ibalizumab: First Global Approval

Anthony Markham

DRUGS (2018)

Add to Collection

Article Pharmacology & Pharmacy

Benralizumab: First Global Approval

A. Markham

DRUGS (2018)

Add to Collection

Article Pharmacology & Pharmacy

Tildrakizumab: First Global Approval

Anthony Markham

DRUGS (2018)

Add to Collection

Article Pharmacology & Pharmacy

Erenumab: First Global Approval

Anthony Markham

DRUGS (2018)

Add to Collection

Article Pharmacology & Pharmacy

Burosumab: First Global Approval

Yvette N. Lamb

DRUGS (2018)

Add to Collection

Review Biochemistry & Molecular Biology

The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules

Beatriz G. de la Torre et al.

MOLECULES (2018)

Add to Collection

Article Pharmacology & Pharmacy

Lanadelumab: First Global Approval

Yahiya Y. Syed

DRUGS (2018)

Add to Collection

Article Pharmacology & Pharmacy

Fremanezumab: First Global Approval

Sheridan M. Hoy

DRUGS (2018)

Add to Collection

Article Pharmacology & Pharmacy

Cemiplimab: First Global Approval

Anthony Markham et al.

DRUGS (2018)

Add to Collection

Article Pharmacology & Pharmacy

Galcanezumab: First Global Approval

Yvette N. Lamb

DRUGS (2018)

Add to Collection

Article Pharmacology & Pharmacy

Moxetumomab Pasudotox: First Global Approval

Sohita Dhillon

DRUGS (2018)

Add to Collection

Article Pharmacology & Pharmacy

Caplacizumab: First Global Approval

Sean Duggan

DRUGS (2018)

Add to Collection

News Item Biotechnology & Applied Microbiology

No added sugar: antibody makers find an upside to 'no fucose'

Ken Garber

NATURE BIOTECHNOLOGY (2018)

Add to Collection

Review Pharmacology & Pharmacy

Monoclonal Antibodies: A Review

Surjit Singh et al.

CURRENT CLINICAL PHARMACOLOGY (2018)

Add to Collection

Article Pharmacology & Pharmacy

Olaratumab: First Global Approval

Matt Shirley

DRUGS (2017)

Add to Collection

Review Medicine, General & Internal

Update on disease-modifying therapies for multiple sclerosis

Diana L. Vargas et al.

JOURNAL OF INVESTIGATIVE MEDICINE (2017)

Add to Collection

Review Biochemistry & Molecular Biology

Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy

Hao Chen et al.

MOLECULES (2017)

Add to Collection

Review Biochemistry & Molecular Biology

The Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type

Beatriz G. de la Torre et al.

MOLECULES (2017)

Add to Collection

Article Medicine, General & Internal

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Johannes Oldenburg et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Pharmacology & Pharmacy

Guselkumab: First Global Approval

Anthony Markham

DRUGS (2017)

Add to Collection

Article Pharmacology & Pharmacy

Inotuzumab Ozogamicin: First Global Approval

Yvette N. Lamb

DRUGS (2017)

Add to Collection

Article Pharmacology & Pharmacy

Durvalumab: First Global Approval

Yahiya Y. Syed

DRUGS (2017)

Add to Collection

Article Pharmacology & Pharmacy

Brodalumab: the first anti- IL-17 receptor agent for psoriasis

L. Puig

DRUGS OF TODAY (2017)

Add to Collection

Article Pharmacology & Pharmacy

Dupilumab: First Global Approval

Matt Shirley

DRUGS (2017)

Add to Collection

Article Pharmacology & Pharmacy

Cerliponase Alfa: First Global Approval

Anthony Markham

DRUGS (2017)

Add to Collection

Article Pharmacology & Pharmacy

Ocrelizumab: First Global Approval

James E. Frampton

DRUGS (2017)

Add to Collection

Article Pharmacology & Pharmacy

Avelumab: First Global Approval

Esther S. Kim

DRUGS (2017)

Add to Collection

Article Pharmacology & Pharmacy

Sarilumab: First Global Approval

Lesley J. Scott

DRUGS (2017)

Add to Collection

Article Pharmacology & Pharmacy

Necitumumab: First Global Approval

Karly P. Garnock-Jones

DRUGS (2016)

Add to Collection

Article Pharmacology & Pharmacy

Atezolizumab: First Global Approval

Anthony Markham

DRUGS (2016)

Add to Collection

Article Pharmacology & Pharmacy

Obiltoxaximab: First Global Approval

Sarah L. Greig

DRUGS (2016)

Add to Collection

Article Pharmacology & Pharmacy

Elotuzumab: First Global Approval

Anthony Markham

DRUGS (2016)

Add to Collection

Article Pharmacology & Pharmacy

Reslizumab: First Global Approval

Anthony Markham

DRUGS (2016)

Add to Collection

Article Pharmacology & Pharmacy

Daratumumab: First Global Approval

Kate McKeage

DRUGS (2016)

Add to Collection

Article Biotechnology & Applied Microbiology

Natpara for the treatment of hypoparathyroidism

Gemma Marcucci et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2016)

Add to Collection

Article Medicine, Research & Experimental

Asfotase alfa therapy for children with hypophosphatasia

Michael P. Whyte et al.

JCI INSIGHT (2016)

Add to Collection

Article Pharmacology & Pharmacy

Idarucizumab: First Global Approval

Celeste B. Burness

DRUGS (2015)

Add to Collection

Article Pharmacology & Pharmacy

Alirocumab: First Global Approval

Anthony Markham

DRUGS (2015)

Add to Collection

Article Pharmacology & Pharmacy

Sebelipase Alfa: First Global Approval

Matt Shirley

DRUGS (2015)

Add to Collection

Article Pharmacology & Pharmacy

Mepolizumab: First Global Approval

Gillian M. Keating

DRUGS (2015)

Add to Collection

Article Pharmacology & Pharmacy

Dinutuximab: First Global Approval

Sohita Dhillon

DRUGS (2015)

Add to Collection

Article Pharmacology & Pharmacy

Evolocumab: First Global Approval

Anthony Markham

DRUGS (2015)

Add to Collection

Article Pharmacology & Pharmacy

Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia

Wanda L. Salzer et al.

PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: WINNERS AND FINALISTS FOR THE PRIX GALIEN USA AWARDS 2013 (2014)

Add to Collection

Article Pharmacology & Pharmacy

Mogamulizumab

Joshuan M. Subramaniam et al.

DRUGS (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.